Keywords: OSI Pharmaceuticals, Astellas, Fiduciary duty, M&A

OSI Pharmaceuticals board under investigation over possible breach of fiduciary duty

Article | 08 March 2010

An investigation on behalf of current long-term shareholders in US drugmaker OSI Pharmaceuticals over potential breaches of fiduciary duty and ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in